PRESERVATION OF LOW-DAMAGE ALLOGENIC HEART VALVE

Information

  • Research Project
  • 3501715
  • ApplicationId
    3501715
  • Core Project Number
    R43HL044233
  • Full Project Number
    1R43HL044233-01
  • Serial Number
    44233
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/15/1990 - 35 years ago
  • Project End Date
    7/15/1990 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    1/15/1990 - 35 years ago
  • Budget End Date
    7/15/1990 - 34 years ago
  • Fiscal Year
    1990
  • Support Year
    1
  • Suffix
  • Award Notice Date
    1/10/1990 - 35 years ago
Organizations

PRESERVATION OF LOW-DAMAGE ALLOGENIC HEART VALVE

The long-term objective of this research is to develop technology and devices for the preservation and drying of porcine bioprosthetic or human allograft heart valves which allows storage in a nonfrozen state (4 degrees-22 degrees). Once rehydrated, the potential advantages of such valves would be longer and more convenient storage pregraft, and longer life spans and reduced thromboembolytic risk postgraft. The potential disadvantage might be well-preserved antigenicity sufficient to elicit immune rejection. Porcine heart valves will be preserved by freezing and molecular distillation drying. After storage at a temperature above freezing, these dry valves will be rehydrated and analyzed for structural degeneration using scanning and transmission electron microscopy. Collagen biodegradation in the valves will be determined by residual hydroxyproline content. Calcification will be determined by atomic absorption analyses after implantation for 21 days in young rats. Later Phase II studies in young sheep will determine whether the early calcification of preserved heart valves is prevented by the quality of the structural and biochemical preservation of the valves. We will then test LifeCell-preserved heart valves in animal models, including determinations of the efficacy of seeding the valves with endothelium postpreservation, and attempts to preserve the viability of the whole valves.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    LIFECELL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SOMERVILLE
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    08876
  • Organization District
    UNITED STATES